ALIVE is a mid-to-late stage HealthTech fund leveraging an exclusive ecosystem of strategic partners, to support and accelerate portfolio companies in their clinical and commercial expansion.

ALIVE’s Ecosystem Offers:

  • Access to KOLs Clinical trials sites
  • >3.5 Million patients & EMRs
  • Clinical need validation Product validation Business model verification
  • Exit strategy development Exposure to potential anchor clients Follow-on investments


Our Representatives

Dudi Klein

Managing Partner, ALIVE Fund

Managing Partner

ALIVE Fund

Michel Habib

Managing General Partner, ALIVE HealthTech Fund

Managing General Partner

ALIVE HealthTech Fund

The Israeli HealthTech Opportunity

Israeli investors have been focusing on Seed and Early-stage investments for decades, increasing the gap between the progress of the HealthTech industry and the financial sector.

ALIVE bridges this widening gap by delivering value to its companies at every stage of the investment process, from product validation to patient bedside distribution.

Our current Portfolio is comprised of 5 promising companies:

Innovalve Bio, Magenta, Medisafe, Cynerio and Beyeonics.

ALIVE's Managing Partners bring a wealth of experience in the Healthcare and HealthTech industries:

Prof. Rafael Beyar, Managing General Partner, Former Director and CEO of Rambam Health Care Campus, Serial Entrepreneur

Michel Habib, Managing General Partner, Senior Biomed Venture Capitalist, Former CEO of Hadasit Bio Holdings

Prof. Ari Shamiss, Managing General Partner, Former CEO of Assuta Medical Centers & Director of Sheba General Hospital

Dudi Klein, Managing Partner, Former Head of Ventures and Innovation, Assuta Medical Centers, Entrepreneur

Our Investment Focus:

Surgical Robotics, Implanted Devices, Minimal Invasive Drug Delivery

Early Diagnostics, Imaging Sensors, Bioinformatics, Personalized Medicine

Telemedicine, Artificial Intelligence, Remote Patient Management, Healthcare IT, Cyber Security

Fund Terms and Metrics

Fund Size - USD150M target, Dec 2021

Initial Closing - USD50M, July 2020

Scope - Lead investor in USD15-40M syndicated rounds

Board - Active Board Membership

Portfolio - 12-15 Companies